Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
The Sustained-Release Cilostazol Tablet of Once Daily 1 Tablet Regimen, Having Improved Releasing Rate And Reduced Side Effect_Korea United Pharm.Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Introducing The Sustained-Release Cilostazol Tablet of Once Daily 1 Tablet Regimen, Having Improved Releasing Rate And Reduced Side Effect...
Contact Heajin Jung
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Cilostazol is a selective inhibitor of 3-type phosphodiesterase (PDE3) with therapeutic focus on increasing cAMP. An increase in cAMP results in an increase in the active form of protein kinase A (PKA

Applications


It is used in the treatment of ischemic symptoms including ulcer, pain and coldness of the extremities in chronic arterial occlusion. It is also indicated in preventing recurrence of cerebral infarction except cardiogenic cerebral embolism


Market Feasibility

Market Sales (2012 IMS 4Q MAT)

Rank CILOSTAZOL 813,113,845 M/S

1 JAPAN COMBINED 586,644,964 72.1%

2 KOREA COMBINED 37,208,579 4.6%

3 BRAZIL RETAIL 29,234,795 3.6%

4 ARGENTINA RETAIL 23,260,231 2.9%

5 USA COMBINED 20,943,089 2.6%

6 SPAIN COMBINED 16,736,025 2.1%

7 GERMANY COMBINED 14,441,999 1.8%

8 CHINA HOSPITAL 13,648,416 1.7%

9 TAIWAN COMBINED 9,682,120 1.2%


10 PHILIPPINES COMBIN 8,275,684 1.0%


Rest of World 53,037,943 6.5%





Type of Business Relationship Sought
We are seeking a collaboration partner
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
GOVERNMENT INSTITUTE